Related Experiment Videos
[DNA topoisomerase inhibitor]
1Dept. of Internal Medicine, Aichi Cancer Center, Nagoya, Japan.
Abstract:
CPT-11 and Topotecan are a new semisynthetic derivative of CPT, and have been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low toxicity against murine tumor. On the other hard, the new antitumor compounds, NC-190 and IST-622 have been shown to inhibit DNA topoisomerase II, and the clinical study are currently under progress. A phase II study of CPT-11 demonstrated that CPT-11 was a very active agent which a acceptable toxicities against patient with advanced non-small cell lung cancer and small cell lung cancer.
Insights
New chemotherapy drugs CPT-11 and Topotecan inhibit DNA topoisomerase I, showing antitumor activity. Other agents targeting topoisomerase II are in clinical trials, with CPT-11 showing promise for lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemotherapy resistance remains a challenge in cancer treatment.
- DNA topoisomerases are crucial targets for anticancer drugs.
- Novel agents targeting topoisomerase I and II are under investigation.
Purpose of the Study:
- To evaluate the antitumor activity and toxicity of CPT-11 and Topotecan.
- To assess the efficacy of novel topoisomerase II inhibitors (NC-190, IST-622).
- To report findings from a Phase II study of CPT-11 in lung cancer patients.
Main Methods:
- In vitro and in vivo studies of CPT-11 and Topotecan against murine tumors.
- Clinical trials for NC-190 and IST-622 targeting DNA topoisomerase II.
- Phase II clinical trial of CPT-11 in patients with advanced non-small cell lung cancer and small cell lung cancer.
Main Results:
- CPT-11 and Topotecan demonstrated significant antitumor activity with low toxicity in preclinical models.
- NC-190 and IST-622 target DNA topoisomerase II, with ongoing clinical studies.
- Phase II study confirmed CPT-11's high activity and acceptable toxicity in advanced lung cancer.
Conclusions:
- CPT-11 and Topotecan are promising semisynthetic derivatives of CPT with potent antitumor effects.
- Inhibition of DNA topoisomerase I and II represents a viable strategy for novel cancer therapies.
- CPT-11 shows significant clinical potential for treating advanced non-small cell and small cell lung cancer.